Biocompatibles' BiodivYsio Stent To Be Sold By Abbott's Perclose Division
This article was originally published in The Gray Sheet
Executive Summary
Biocompatibles' BiodivYsio phosphorylcholine-coated stent will be marketed in the U.S. by a direct sales force of about 150 from Abbott Labs' Perclose division, following FDA approval Oct. 3.
You may also be interested in...
Abbott Plays It Safe, Obtains Cordis License For BiodivYsio Launch
Abbott Labs' U.S. launch of British partner Biocompatibles' phosphorylcholine-coated BiodivYsio coronary stent following FDA approval July 5 will not include a rapid-exchange version of the device, according to the company.
Abbott Plays It Safe, Obtains Cordis License For BiodivYsio Launch
Abbott Labs' U.S. launch of British partner Biocompatibles' phosphorylcholine-coated BiodivYsio coronary stent following FDA approval July 5 will not include a rapid-exchange version of the device, according to the company.
Abbott, Biocompatibles To Initiate Drug-Coated Stent Trial By Year-End
Abbott Laboratories expects to begin human clinical trials of a drug-coated stent for in-stent restenosis with partner Biocompatibles by the end of 2001.